Jim Wilson’s next venture, a surprise startup shutdown, & Lilly’s Zepbound strategy
What’s behind the “great abandonment” in gene therapy R&D? How does a startup spend $213…
Category: gene editing
STAT+: Tome Biosciences files notice to lay off nearly entire staff
High-profile gene editing startup Tome Biosciences said in a legal filing Friday that it will…
STAT+: Tome Biosciences, once a high-flying gene-editing startup, is floundering
Buzzy gene-editing startup Tome Biosciences is floundering, just nine months after launching with $213 million…
STAT+: How Pfizer’s grand gene therapy ambitions crumbled
A decade ago, Pfizer began investing heavily in gene therapy, bringing in experimental treatments for…
STAT+: Trying to outrun her prion disease, researcher creates powerful epigenetic editor in mice
Sonia Vallabh always thought genome editing wouldn’t be an option. It was such an obvious…
STAT+: Intellia’s CRISPR-based treatment dramatically reduced patients’ swelling attacks in small trial
Intellia Therapeutics said Saturday that the first 10 patients to receive a CRISPR-based treatment for…
Verve Therapeutics ‘pauses’ tests of its gene editor for heart disease and prioritizes a backup treatment
Verve Therapeutics said Tuesday that it is pausing testing of its closely watched gene-editing treatment…
Watch: What is in utero gene editing?
Recently approved gene therapies offer patients one-time, potentially curative treatments for genetic diseases such as…
STAT+: Feng Zhang’s year-old CRISPR delivery startup Aera lays off quarter of staff
Aera Therapeutics, a startup launched by the CRISPR pioneer Feng Zhang last year to solve…
STAT+: Prime Medicine, Mukherjee’s Myeloid Therapeutics clash over genome-editing deal
The closely watched gene editing startup Prime Medicine is embroiled in a multimillion-dollar dispute with…
In historic decision, FDA approves a CRISPR-based medicine for treatment of sickle cell disease
The Food and Drug Administration on Friday approved the world’s first medicine based on CRISPR…
STAT+: CRISPR’s pioneers reflect on the first gene-editing treatment
The revolution started in silence. Jennifer Doudna and Emmanuelle Charpentier, now Nobelists, published their first…
Key questions (and answers) about the historic approval of a CRISPR-based medicine
History just happened. For the first time, a regulator has cleared a treatment using CRISPR,…
STAT+: Eli Lilly to pay $200 million for Beam’s share of drugs from gene-editing firm Verve
Eli Lilly said Tuesday that it will pay $200 million to gene-editing firm Beam Therapeutics…
STAT+: In major test for prime editing, scientists succesfully correct mutations in monkeys
Prime Medicine said Friday it successfully used a new, ultra-versatile form of genetic surgery called…
Listen: Live from the 2023 STAT Summit
What if CRISPR isn’t all that commercial? How does the NurOwn story end? And how…
STAT+: Beam Therapeutics to lay off 20% of its staff, reevaluate programs as it cuts costs
Beam Therapeutics said Monday morning it would lay off 20% of its staff — or…
In major test for eGenesis, gene-edited pig kidneys kept monkeys alive for more than two years
Scientists at a Massachusetts-based biotechnology company and their academic research partners reported Wednesday that an…
STAT+: Scientists inch closer to single-shot gene editing cure for blood disorders
What is the best way to fix faulty blood cells, and do so for the…
STAT+: New research may give geneticists a long-sought tool: a targeted protein delivery device
Mark Hurst just wanted to kill some bugs. A newly credentialed bacteriologist working for the…
STAT+: CRISPR? Nah. A new startup bets on an old approach to gene editing
Before there was CRISPR, aspiring genome editors relied on an island of misfit, less elegantly…
Virtual Event: CRISPR Quest
Editor’s note: A livestream of the event will be embedded below at 1 p.m. ET…
STAT+: Moderna, making billions from its vaccine, bets on a genome-editing startup
Moderna, flush with cash thanks to its blockbuster Covid-19 vaccine, made waves back in August…